Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17018037 | 1.00 | NNMT (0.40) | NNMTPDE10AADRA2APNMTADRA2B | |
| SCHEMBL20075991 | 0.83 | NNMT (0.56) | NNMTADRA2APNMTADRA2BADRA2C | |
| SCHEMBL23938133 | 0.81 | NNMT (0.41) | NNMTPDE10AAR | |
| SCHEMBL21745578 | 0.81 | NNMT (0.41) | NNMTPDE10AAR | |
| SCHEMBL29349046 | 0.80 | NNMT (0.31) | NNMT | |
| SCHEMBL20731022 | 0.80 | NNMT (0.43) | NNMTPDE10AAR | |
| SCHEMBL23938078 | 0.80 | NNMT (0.40) | NNMTPDE10AAR | |
| SCHEMBL13352184 | 0.78 | NNMT (0.32) | NNMTAKR1B1 | |
| SCHEMBL13352183 | 0.78 | NNMT (0.32) | NNMTAKR1B1 | |
| SCHEMBL24823955 | 0.76 | AKR1B1 (0.42) | NNMTAKR1B1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102404-A1 | THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102404-A1 | THYROID STIMULATING HORMONE RECEPTOR (TSHR) ANTAGONISTS AND USES THEREOF | TSHR, TRHR, THRB | NNMT 3486/4885PDE10A 1664/4885ADRA2A 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.